



## FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

To be completed by Requesting provider				
Strength:				
Duration of Therapy:				

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):			
1	Patient Name: Phy	lame: Physician Name:		
	Address:			
	Sponsor ID #	Phone #:		
	Date of Birth: S	Secure Fax #:		
Step				
2	1. Has the patient received this medication under	Yes	□No	
	the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for Vyleesi	(subject to verification)	Proceed to question 2	
		Proceed to question 10		
	2. Is the patient GREATER THAN or EQUAL to 18	Yes	□No	
	years of age?	Proceed to question 3	STOP	
			Coverage not approved	
	3. Is the patient a premenopausal woman with a	🗌 Yes	□No	
	documented diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD)?	Proceed to question 4	STOP	
			Coverage not approved	
	4. Is the patient's diagnosis characterized by low	🗌 Yes	□ No	
	sexual desire that causes marked distress or interpersonal difficulty?	Proceed to question 5	STOP	
			Coverage not approved	
	5. Is the patient's decreased sexual desire caused	🗌 Yes	□No	
	by any of the following:	STOP	Proceed to question 6	
	co- existing medical or psychiatric condition	Coverage not approved		
	problems with the relationship			
	effects of a medication or drug substance			
	6. Has the patient been informed that other	🗌 Yes	□No	
	treatment options such as cognitive-behavior therapy, sexual therapy, or couples therapy, may	Proceed to question 7	STOP	
	provide benefit without risk of side effects?		Coverage not approved	

## Prior Authorization Request Form for bremelanotide injection **(Vyleesi)**

7.	Does the patient have uncontrolled hypertension or known cardiovascular disease?	☐ Yes STOP		
		Coverage not approved	Proceed to question 8	
8.	Has the patient been counseled on the risks of focal hyperpigmentation (skin discoloration) and	Yes Proceed to question <b>9</b>	□No STOP	
	severe nausea?		Coverage not approved	
9.	Does the patient agree to use effective contraception while taking Vyleesi?	☐ Yes	□No	
	contraception while taking vytecsh	Sign and date below	STOP	
			Coverage not approved	
10.	Has the patient had documented improvements in symptoms without serious side effects?	🗌 Yes	□No	
		Sign and date below	STOP	
			Coverage not approved	
entite the choice is two to the best of my lunguiled as Disess size and date.				

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[19 February 2020]

For Internal Use Only			
Approved:	Duration of Approval:month(s)		
Denied:	Authorized By:		
Incomplete/Other:	PA#:		
Date Faxed to MD:	Date Decision Rendered:		